Table 3 Patients and tumor characteristics of the selected studies
From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Authors (year of publication) [reference] | Number of patients underwent SBRT | Type of Study | Primary Tumor site | Number of metastases underwent to SBRT (upper limit) | Type of oligometastases and organ involved (liver, lung, bone, nodes, brain…) | Metastases size (cm) | SBRT (median total dose/fraction) | Biologically equivalent dose (Median value) | Systemic Therapy |
|---|---|---|---|---|---|---|---|---|---|
Weickhardt et al. (2012) [29] | 25 | Retrospective | NSCLC | <=4 | Oligoprogressive (Brain,Lung) | N.S. | 15–54Gy, median 40Gy | N.S. | Crizotinib, Erlotinib |
Iyengar et al. (2014) [23] | 24 (52 lesions) | Phase II | NSCLC | <=3 | Oligorecurrent (Lung; Liver; Kidney; Bone; Adrenal; Mediastinum) | N.S. | 19–40/1–5 | 55.1–72 | Erlotinib |
Borghetti et al. (2019) [25] | 49 | Retrospective | NSCLC | <=4 | Oligoprogressive (Brain, Lung, Bone) | N.S. | mean 80 Gy, range 60–178 Gy | > 60 | N.S. |
Qiu et al. (2017) [24] | 46 | Retrospective | NSCLC | < 5 | Oligoprogressive | N.S. | N.S. | N.S. | N.S. |
Rossi et al. (2019) [26] | 30 | Retrospective | NSCLC | N.S. | Oligoprogressive | N.S. | N.S. | N.S. | Afatinib, Gefitinib |
Weiss et al. (2019) [30] | 25 | Retrospective | NSCLC | N.S. | Oligoprogressive | N.S. | N.S. | N.S. | Erlotinib |
Chan OSH et al. (2018) [31] | 18 | Phase II | NSCLC | 34 | Oligoprogressive | N.S. | N.S. | N.S. | TKI therapy |
Xu et al. (2018) [27] | 51 | Retrospective | NSCLC | N.S. | Oligoprogressive | N.S. | 27–21–33-37.5/1–1–3-5 | 65.8 | Gefitinib, Erlotinib, Icotinib |